A Phase 1 interventional study of GS-3583 and Zimberelimab in Advanced Solid Tumors, sponsored by Gilead Sciences. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-03.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is planned to be conducted in 2 parts: Part 1: Dose Escalation and Part 2: Safety Run-In and Randomized Expansion.
The primary objectives of Part 1 are 1) To characterize the safety and tolerability of GS-3583 as monotherapy in participants with advanced solid tumors. 2) To determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of GS-3583 as monotherapy in participants with advanced solid tumors.
The primary objectives of Part 2 is to assess the safety and tolerability and to determine the RP2D of GS-3583 in combination with zimberelimab (ZIM) and platinum (cisplatin or carboplatin) + 5-fluorouracil (5-FU) chemotherapy in participants with head and neck squamous cell carcinoma (HNSCC) (Cohort A) or in combination with docetaxel in participants with non-small cell lung cancer (NSCLC) (Cohort B).
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Active or history of disease that has required systemic treatment within 2 years of the start of study treatment (ie, with use of disease-modifying agents, corticosteroids, or drugs)
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced solid tumors will receive GS-3583 675 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
Drug: GS-3583
Participants with advanced solid tumors will receive GS-3583 2000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
Drug: GS-3583
Participants with advanced solid tumors will receive GS-3583 6000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
Drug: GS-3583
Participants with advanced solid tumors will receive GS-3583 12000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
Drug: GS-3583
Participants with advanced solid tumors will receive GS-3583 20000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
Drug: GS-3583
Participants with head and neck squamous cell carcinoma (HNSCC) will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + ZIM 360 mg, on Day 1 of each 21-day cycle up to 105 weeks + cisplatin 100 mg/m\^2 of BSA on Day 1 of each 21-day cycle up to 6 cycles + carboplatin area under the curve 5 mg/mL/min on Day 1 of each 28- day cycle up to 6 cycles + 5-5-flourouracil (5-FU) 1000 mg/m\^2 of BSA/day on Days 1 to 4 of 21-day cycle up to 6 cycles.
Drug: GS-3583 · Drug: Zimberelimab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil
Participants with non-small cell lung cancer (NSCLC) will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + docetaxel 75 mg/m\^2 on Day 1 of each 21-day cycle until 1 or more criteria for discontinuation are met.
Drug: GS-3583 · Drug: Docetaxel
Participants with HNSCC will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + ZIM 360 mg, on Day 1 of each 21-day cycle up to 105 weeks + cisplatin 100 mg/m\^2 of BSA on Day 1 of each 21-day cycle up to 6 cycles + carboplatin area under the curve 5 mg/mL/min on Day 1 of each 21-day cycle up to 6 cycles + 5-FU 1000 mg/m\^2 of BSA/day on Days 1 to 4 of 21-day cycle up to 6 cycles.
Drug: GS-3583 · Drug: Zimberelimab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil
Participants with HNSCC will receive ZIM 360 mg, on Day 1 of each 21-day cycle up to 105 weeks + cisplatin 100 mg/m\^2 of BSA on Day 1 of each 21-day cycle up to 6 cycles + carboplatin area under th e curve 5 mg/mL/min on Day 1 of each 21-day cycle up to 6 cycles + 5-FU 1000 mg/m\^2 of BSA/day on Days 1 to 4 of 21-day cycle up to 6 cycles.
Drug: Zimberelimab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil
Participants with NSCLC will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + docetaxel 75 mg/m\^2 on Day 1 of each 21-day cycle until 1 or more criteria for discontinuation are met.
Drug: GS-3583 · Drug: Docetaxel
Participants with NSCLC will receive docetaxel 75 mg/m\^2 on Day 1 of each 21-day cycle until 1 or more criteria for discontinuation are met.
Drug: Docetaxel
Administered as an intravenous (IV) infusion
Administered as an IV infusion
Administered as an IV infusion
Administered as an IV infusion
Administered as an IV infusion
Administered as an IV infusion
Parts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
DLT was defined as any toxicity (hematologic, non-hematologic, dosing/procedures-related toxicities, or grade 5 event (ie death)) occurring with GS-3583 monotherapy during the DLT assessment period (from Day 1 up to Day 28) considered at least possibly related to GS-3583 monotherapy.
Time frame: Part 1: Day 1 through Day 28; Part 2: Day 1 through Day 21
Parts 1 and 2: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
TEAEs were AEs with onset dates on or after the first dose and up to 90 days after the date of the last dose of study treatment or the day before initiation of subsequent therapy, whichever occurred first. TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.
Time frame: First dose date up to last dose date plus 90 days (Up to 4 months)
Parts 1 and 2: Percentage of Participants With Laboratory Abnormalities According to the NCI CTCAE Version 5.0
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time, up to 90 days after the last dose of study drug or the day before initiation of subsequent therapy, whichever occurred first. A treatment-emergent laboratory abnormality severity was graded according to the NCI CTCAE version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.
Time frame: First dose date up to last dose date plus 90 days (Up to 4 months)
Parts 1 and 2: Percentage of Participants With GS-3583 Anti-drug Antibodies (ADAs) at Any Visit
Participants were monitored for the development of ADAs throughout their treatment period with GS-3583 and at the end of study.
Time frame: Cycles 1and 3,pre-dose,End of Infusion (EOI);2,6 hours;Days 2,3,5,8,15 post Day 1EOI;Day 15:Cycle 1:predose and EOI;2 hours post EOI;Cycle 3:336 hours and Day 24 post EOI(Cycle length = 28 days in Part 1; 21 days for Part 2;infusion duration=60 minutes)
Part 1: Pharmacokinetic (PK) Parameter: AUCtau of GS-3583
AUCtau is defined as the area under the concentration versus time curve over the dosing interval where tau = 15 days.
Time frame: Cycles 1 and 3, pre-dose, EOI; 2, 6 hours; Days 2, 3, 5, 8, 15 post Day 1 EOI; Day 15:Cycle 1:predose and EOI; 2 hours post EOI;Cycle 3:336 hours and Day 24 post EOI (Cycle length for all cycles=28 days in Part 1; Infusion duration=60 minutes)
Part 1: PK Parameter: Cmax of GS-3583
Cmax is defined as the maximum observed plasma concentration.
Time frame: Cycles 1 and 3,pre-dose,EOI;2, 6 hours;Days 2, 3, 5, 8, 15 post Day 1 EOI;Day 15:Cycle 1:predose and EOI;2 hours post EOI;Cycle 3:336 hours and Day 24 post EOI (Cycle length for all cycles=28 days in Part 1;Infusion duration=60 minutes)
Part 1: PK Parameter: Tmax of GS-3583
Tmax is defined as the time to reach maximum observed plasma concentration (Tmax).
Time frame: Cycles 1 and 3, pre-dose, EOI; 2, 6 hours; Days 2, 3, 5, 8, 15 post Day 1 EOI; Day 15:Cycle 1:predose and EOI; 2 hours post EOI; Cycle 3:336 hours and Day 24 post EOI (Cycle length for all cycles=28 days in Part 1; infusion duration=60 minutes)
Part 2: Confirmed Objective Response Rate (ORR)
Confirmed ORR is defined as the percentage of participants who have achieved confirmed CR or PR according to RECIST V1.1 and assessed by the investigator. Per RECIST V1.1, CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)
Part 2: Progression-free Survival (PFS)
PFS is defined as the time from first dose date until first date of disease progression (PD) or death from any cause, whichever comes first as measured per RECIST V1.1 as assessed by the investigator. Per RECIST V1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)
Part 2: Duration of Response (DOR)
DOR was defined as time of first response (CR or PR) per RECIST V1.1 as assessed by the investigator until the date of first documented disease progression or death, whichever comes first. Per RECIST V1.1, CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)
Part 2: Overall Survival (OS)
Overall survival is defined as the time from randomization until death from any cause.
Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)
Part 2: Disease Control Rate (DCR)
DCR was defined as percentage of participants with a best overall confirmed response of CR or PR or stable disease. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)
Part 2: PK Parameters: Cmax for GS-3583
Cmax is defined as the maximum observed serum concentration of drug.
Time frame: Safety-run In:Cycles 1 and 3: Day 1, predose, EOI; 2, 6 hours, Days 8, 15; Part 2 all arms:Cycles 2 and 5: Day 1 predose, EOI and every odd cycles; 60-day FU; (Cycle length of all cycles = 21 days in Part 2; Infusion duration=60 minutes)
Part 2: PK Parameter: Tmax for GS-3583
Tmax is defined as the time (observed time point) of the occurrence of Cmax.
Time frame: Safety-run In: Cycles 1, and 3: Day 1, predose, EOI; 2, 6 hours, Days 8, Day 15; Part 2: all arms: Cycles 2 and 5: Day 1 predose, EOI and every odd cycles; 6-day FU; (Cycle length of all cycles = 21 days in Part 2; Infusion duration=60 minutes)
Part 2: PK Parameter: AUCtau of GS-3583
AUCtau is defined as the area under the concentration versus time curve over the dosing interval.
Time frame: Safety-run In: Cycles 1, and 3: Day 1, predose, EOI; 2, 6 hours, Days 8, Day 15; Part 2: all arms: Cycles 2 and 5: Day 1 predose, EOI and every odd cycles; 6-day FU; (Cycle length of all cycles = 21 days in Part 2; Infusion duration=60 minutes)
Participants were enrolled at study sites in the United States. This study was planned to be conducted in 2 parts: Part 1: Dose Escalation Part and Part 2: Safety Run-In and Randomized Expansion Part. Due to early termination of the study, Part 2 was not conducted. Results are reported only for Part 1 of the study.
| Milestone | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 3 | 3 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 3 | 3 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 3 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
DLT was defined as any toxicity (hematologic, non-hematologic, dosing/procedures-related toxicities, or grade 5 event (ie death)) occurring with GS-3583 monotherapy during the DLT assessment period (from Day 1 up to Day 28) considered at least possibly related to GS-3583 monotherapy.
| percentage of participants | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) | — | 0 | 0 | 0 | 0 | — | — | — | — | — | — |
TEAEs were AEs with onset dates on or after the first dose and up to 90 days after the date of the last dose of study treatment or the day before initiation of subsequent therapy, whichever occurred first. TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.
| percentage of participants | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | — | 100 | 100 | 100 | 100 | — | — | — | — | — | — |
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time, up to 90 days after the last dose of study drug or the day before initiation of subsequent therapy, whichever occurred first. A treatment-emergent laboratory abnormality severity was graded according to the NCI CTCAE version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.
| percentage of participants | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Percentage of Participants With Laboratory Abnormalities According to the NCI CTCAE Version 5.0 | — | 100 | 100 | 100 | 100 | — | — | — | — | — | — |
Participants were monitored for the development of ADAs throughout their treatment period with GS-3583 and at the end of study.
| percentage of participants | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Percentage of Participants With GS-3583 Anti-drug Antibodies (ADAs) at Any Visit | — | 33.3 | 33.3 | 0 | 0 | — | — | — | — | — | — |
AUCtau is defined as the area under the concentration versus time curve over the dosing interval where tau = 15 days.
| h*ng/mL | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg |
|---|---|---|---|---|---|
| Cycle 1 | — | 82100 ± 19900 | 249000 ± 124000 | 352000 ± 41300 | 832000 ± 223000 |
Cmax is defined as the maximum observed plasma concentration.
| ng/mL | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg |
|---|---|---|---|---|---|
| Cycle 1 | — | 643 ± 36.3 | 1860 ± 562 | 2520 ± 244 | 5800 ± 1460 |
Tmax is defined as the time to reach maximum observed plasma concentration (Tmax).
| hours (h) | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg |
|---|---|---|---|---|---|
| Cycle 1 | — | 1.1 (1.0 to 1.1) | 2.0 (1.1 to 5.6) | 1.1 (1.1 to 2.0) | 1.7 (1.2 to 2.1) |
Confirmed ORR is defined as the percentage of participants who have achieved confirmed CR or PR according to RECIST V1.1 and assessed by the investigator. Per RECIST V1.1, CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
No measurements were reported for this outcome.
PFS is defined as the time from first dose date until first date of disease progression (PD) or death from any cause, whichever comes first as measured per RECIST V1.1 as assessed by the investigator. Per RECIST V1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
No measurements were reported for this outcome.
DOR was defined as time of first response (CR or PR) per RECIST V1.1 as assessed by the investigator until the date of first documented disease progression or death, whichever comes first. Per RECIST V1.1, CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
No measurements were reported for this outcome.
Overall survival is defined as the time from randomization until death from any cause.
No measurements were reported for this outcome.
DCR was defined as percentage of participants with a best overall confirmed response of CR or PR or stable disease. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
No measurements were reported for this outcome.
Cmax is defined as the maximum observed serum concentration of drug.
No measurements were reported for this outcome.
Tmax is defined as the time (observed time point) of the occurrence of Cmax.
No measurements were reported for this outcome.
AUCtau is defined as the area under the concentration versus time curve over the dosing interval.
No measurements were reported for this outcome.
Collected over Up to 14.8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cohort 1: GS-3583 675 μg | — | — | — |
| Part 1: Cohort 2: GS-3583 2000 μg | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 1: Cohort 3: GS-3583 6000 μg | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: Cohort 4: GS-3583 12000 μg | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 1: Cohort 5: GS-3583 20000 μg | 2/4 (50%) | 1/4 (25%) | 4/4 (100%) |
| Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy | — | — | — |
| Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy | — | — | — |
| Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy | — | — | — |
| Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy | — | — | — |
| Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy | — | — | — |
| Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy | — | — | — |
| Event | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | — | 1/3 | 0/3 | 0/3 | 0/4 | — | — | — | — | — | — |
| Large intestinal obstructionGastrointestinal disorders | — | 1/3 | 0/3 | 0/3 | 0/4 | — | — | — | — | — | — |
| Small intestinal obstructionGastrointestinal disorders | — | 0/3 | 1/3 | 1/3 | 0/4 | — | — | — | — | — | — |
| SepsisInfections and infestations | — | 0/3 | 0/3 | 1/3 | 0/4 | — | — | — | — | — | — |
| HyponatraemiaMetabolism and nutrition disorders | — | 1/3 | 0/3 | 0/3 | 0/4 | — | — | — | — | — | — |
| Cerebrovascular accidentNervous system disorders | — | 1/3 | 0/3 | 0/3 | 0/4 | — | — | — | — | — | — |
| Second primary malignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps) | — | 0/3 | 0/3 | 0/3 | 1/4 | — | — | — | — | — | — |
| Event | Part 1: Cohort 1: GS-3583 675 μg | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy | Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | — | 2/3 | 1/3 | 3/3 | 2/4 | — | — | — | — | — | — |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | — | 3/3 | 1/3 | 0/3 | 0/4 | — | — | — | — | — | — |
| Abdominal painGastrointestinal disorders | — | 0/3 | 2/3 | 2/3 | 0/4 | — | — | — | — | — | — |
| ConstipationGastrointestinal disorders | — | 0/3 | 0/3 | 2/3 | 1/4 | — | — | — | — | — | — |
| Bone painMusculoskeletal and connective tissue disorders | — | 0/3 | 2/3 | 0/3 | 0/4 | — | — | — | — | — | — |
| NauseaGastrointestinal disorders | — | 1/3 | 1/3 | 1/3 | 2/4 | — | — | — | — | — | — |
| ThrombocytopeniaBlood and lymphatic system disorders | — | 0/3 | 0/3 | 1/3 | 0/4 | — | — | — | — | — | — |
| Abdominal pain upperGastrointestinal disorders | — | 0/3 | 0/3 | 1/3 | 0/4 | — | — | — | — | — | — |
| AscitesGastrointestinal disorders | — | 1/3 | 0/3 | 0/3 | 0/4 | — | — | — | — | — | — |
| DiarrhoeaGastrointestinal disorders | — | 0/3 | 1/3 | 0/3 | 1/4 | — | — | — | — | — | — |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 1 | 2 | 1 | 4 |
| >=65 years | 3 | 2 | 1 | 3 | 9 |
| Age, Continuous(years) | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Total |
|---|---|---|---|---|---|
| Mean | 72 ± 1.2 | 63 ± 17.6 | 58 ± 15.3 | 70 ± 7.5 | 66 ± 11.8 |
| Sex: Female, Male(Participants) | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 0 | 1 | 6 |
| Male | 1 | 0 | 3 | 3 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 1 | 1 | 4 |
| Not Hispanic or Latino | 3 | 1 | 2 | 3 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 3 | 3 | 3 | 12 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part 1: Cohort 2: GS-3583 2000 μg | Part 1: Cohort 3: GS-3583 6000 μg | Part 1: Cohort 4: GS-3583 12000 μg | Part 1: Cohort 5: GS-3583 20000 μg | Total |
|---|---|---|---|---|---|
| United States | 3 | 3 | 3 | 4 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Nov 2022, 19 months.
Results were first posted in Sep 2024, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zimberelimab · Docetaxel